Verastem (VSTM) Q3 2026 Earnings Call Transcript

Verastem (VSTM) reported Q3 2026 earnings, highlighting FDA acceptance of its new blister pack NDA with a February 2027 PDUFA date. The company shared positive clinical data for VS-7375 in pancreatic, colorectal, and lung cancers, raising $250M to fund operations into 2028. Q3 revenue for AVMAPKI FAKZYNJA CO-PACK was $24M, with plans to expand its use in approved indications. CEO Dan Patterson will step down at the end of 2026, succeeded by Michael Bailey.

Original reporting
Published Nov 6, 2026, 11:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 12:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Verastem (VSTM) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$VSTMBullishMed
01

Why it matters

The FDA priority‑review acceptance is the most material new development, potentially driving share price higher.

02

Market read

Regulatory progress for a late‑stage oncology asset can move the stock and influence peer valuations.

03

What to watch

The upcoming Phase III trial timeline and competitive landscape in KRAS‑mutated cancers.

Relevance 8/10Novelty 8/10Timing: today

Background

Verastem discussed its Q3 2026 earnings call, highlighting clinical data, a $250 M capital raise, and an executive transition.

Company-level read

Ticker impact

$VSTMBullishHigh confidence
Context

FDA accepted Verastem's new blister pack NDA for priority review with a PDUFA date in February 2027.

Expected impact

potential upside as the market prices in the priority review status

Evidence & confidence

A priority review signals a faster path to market, which is material for a biotech with an unmet‑need program.

Market effects

Other KRAS‑targeted oncology firms may see increased attention as the field gains momentum.

US biotech sector could benefit from the regulatory milestone.

Limited to biotech investors; no broad market effect.

Counterpoint

If the FDA later requests additional data, the initial upside could be short‑lived.

Key entities

  • Verastem

    US‑listed biotech developing KRAS‑targeted therapies.

  • Michael Bailey

    Incoming CEO, former AVEO/LG Chem executive.

Related articles

$VSTMMed

VSTM: 900 mg advances across indications, with three Phase III starts planned and a data-rich 2027 ahead

Verastem, Inc. (VSTM) is advancing its 900 mg dose of VS-7375 across multiple indications, focusing on selective target inhibition and chemo-free combinations. The company plans to initiate three Phase III trials and expects multiple clinical updates in 2027, with cash reserves lasting through the first half of 2028, according to its 8th Annual Wolfe Research Healthcare Conference.

$VSTMMedAI 8/10

What Verastem (VSTM) Said on Its Q3 Earnings Call

Verastem (VSTM) reported Q3 earnings, highlighting clinical trial data for VS-7375 in pancreatic, colorectal, and lung cancers. The company saw positive responses in early-stage trials and plans to initiate phase III trials. Verastem raised $250M in an October offering, ending Q3 with $422.8M in cash. The company expects to complete enrollment in some trials by year-end and in others by mid-2027.

$NVCRLowAI 8/10

Novocure partners with Verastem on pancreatic cancer trial

Novocure (NVCR) and Verastem Oncology (VSTM) partner to test Tumor Treating Fields therapy with VS-7375 for pancreatic cancer. Trial to start in 2027, focusing on safety and tolerability in 25 patients. Novocure will fund and manage the trial, while Verastem supplies the drug. The treatment aims to combine chemotherapy, VS-7375, and Tumor Treating Fields. Pancreatic cancer has a low survival rate and limited treatment options.

$NVCRLowAI 8/10

A planned trial will test electric-field therapy with chemotherapy and an experimental drug.

Novocure (NVCR) and Verastem Oncology plan a clinical trial to evaluate Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem’s experimental drug VS-7375 for locally advanced pancreatic cancer. The trial, expected to start in 2027, will assess safety and preliminary efficacy in about 25 patients. Novocure will manage and fund the trial, while Verastem will supply the drug. Both companies believe the combination could offer a new treatment approach for this challenging cancer.